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1. Introduction
An aberrant composition of the intestinal microbiota, 
or dysbiosis, is associated with a variety of intestinal and 
other disorders, such as infections and allergies, in humans 
(Alonso and Guarner, 2013). In the beginning of the 1900s, 
it was suggested for the first time to administrate ‘healthy’ 
bacteria to restore the microbial composition and thereby 
inducing a therapeutic effect (Metchnikoff, 1907). One 
approach to modulate the intestinal flora is the use of 
probiotics or prebiotics. Probiotics are live microorganisms 
that, when administered in adequate amounts, confer a 
health benefit on the host (FAO, 2001; Sanders, 2008). 
Prebiotics are non-viable food components that modulate 
the microbiota and thereby confer a health benefit on the 
host (Pineiro et al., 2008). When probiotics are administered 
in combination with prebiotics, it is referred to as a 
synbiotic (De Vrese and Schrezenmeir, 2008). There is 
still some controversy regarding the efficacy of pro- and 
synbiotics, as studies report inconsistent results. This might 
be attributable to different study populations (and power 
of the study) and conditions, probiotic strains, dosage and 
study duration (Sanders et al., 2013).
However, an ever expanding number of suitably powered, 
randomised controlled trials (RCT) with probiotic 
supplementation demonstrate encouraging results for 
particular conditions in infants. For instance, a double-
blind RCT by Saavedra et al. (1994) demonstrated 
that administration of Streptococcus thermophilus and 
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Abstract
In this study, we systematically evaluated safety aspects in clinical trials with probiotics and synbiotics in young infants 
(0-2 years of age). This study is an update of earlier reports and covers the recent literature from 2008-2013. The 
safety evaluation is performed along the Common Terminology Clinical Adverse Events (CTCAE) version 4.0 scale, 
hereby also providing guidance for future studies. Safety aspects are represented and related to number of participants 
per probiotic strain/culture, study duration, dosage, clinical condition and selected afflictions. The results show a 
deficiency in the precise reporting and classification of adverse events in most studies. Analysis of 57 clinical trials 
with probiotics and synbiotics in combination with eight follow-up studies indicate that probiotic administration 
to infants between 0 and 24 months is safe with regard to the evaluated strains in infants with a particular health 
status or susceptibility. Most adverse events and serious adverse events were considered unrelated to the study 
product, and there were no major safety concerns. Almost all studies concluded that none of the adverse effects 
were related to the study product; the study products are generally well tolerated. Finally, inconsistent, imprecise 
and potentially incomplete reporting as well as the variation in probiotic strains, dosages, administration regimes, 
study populations and reported outcomes, greatly limit the generalizability of conclusions and argue convincingly 
for obligatory and standardised behaviour on adverse events (CTCAE) reporting in ‘food’ studies.
Keywords: prebiotics, probiotics, health benefits, food safety legislation, children
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Bifidobacterium bifidum in infants aging from 5 to 24 
months reduced the incidence of acute diarrhoea and 
rotavirus shedding. Additionally, meta-analyses indicate 
that probiotic supplementation results in a reduction 
in diarrhoeal duration as well as a reduced incidence of 
Clostridium difficile induced diarrhoea (Goldenberg et al., 
2013; Sanders et al., 2013). Probiotic interventions have also 
clearly demonstrated to significantly reduce the incidence 
of necrotising enterocolitis (NEC) in very-low-birth-weight 
(<1,500 g) preterm infants (Ganguli and Walker, 2011; Lin 
et al., 2013). Besides the beneficial effects of probiotics 
on gastrointestinal disorders, clinical data also indicate a 
potential in other disorders, such as the prevention of atopic 
dermatitis by Lactobacillus rhamnosus GG supplementation 
(Kalliomäki et al., 2001).
The intestinal microbiota supports the human body in 
various physiologic and metabolic functions, such as 
energy storage, fermentation, synthesising amino acids 
and vitamins (Vyas and Ragnanathan, 2012). Equally 
important is the major role of the intestinal microbiota in 
the development, maturation and maintenance of a ‘normal’ 
immune system (Kamada et al., 2013). Studies using germ-
free mice demonstrate a poorly developed immune system 
and an altered intestinal morphology (Ping and LanJuan, 
2012). Gut bacteria are able to produce short-chain fatty 
acids, such as acetate, propionate, and butyrate, which 
acidify the intestinal lumen, thereby inhibiting pathogenic 
growth (Alonso and Guarner, 2013). In humans, the 
gut microbiota colonises the mucosal surface, thereby 
competing with potential pathogens for nutrition and 
binding sites (Kamada et al., 2013). Additionally, some 
commensal bacteria are able to produce antimicrobial and 
antifungal peptides, preventing pathogens from getting a 
foothold in the intestines (Hardy et al., 2013). Intestinal 
colonisation is also associated with a higher secretory 
immunoglobulin A concentration, which prevents microbes 
from penetrating the epithelium. Finally, the gut microbiota 
stimulates innate and adaptive immune response. Dendritic 
cells and Toll-like receptors are in close contact with the 
intestinal microbiota, probing in the lumen, and thereby 
shape the natural killer (NK)-cell, T-cell and B-cell response 
(Hardy et al., 2013).
The foetal intestine is sterile in the womb and microbial 
colonisation is initiated due to extensive contact in the 
birth canal during labour. The intestinal microbiota 
further matures by close contact with the environment 
and breast milk (Clemente et al., 2012). Neonates that fail 
to acquire the normal intestinal ecosystem are at risk of 
developing diseases, also later in life. Studies demonstrated 
that preterms, predominantly colonised by bacteria in the 
intensive care unit, tend to have a higher risk to develop 
an allergy and inflammatory bowel syndrome (Hickey et 
al, 2012). Formula-fed infants have a more heterogeneous 
microbial composition, which is associated with a higher 
incidence of infections and more Clostridia species in the 
intestine compared to breast-milk fed infants (Hascoët et 
al., 2011).
There are several concerns regarding the potential risk 
associated with probiotic use, especially in an immature or 
compromised gut. The bacteria may translocate through the 
gastrointestinal barrier, thereby causing invasive infections 
leading to bacteraemia or sepsis. Another concern is the 
possibility that the metabolic activity of the microbial 
products might be toxic to the host. Additionally, probiotics 
could even have an adverse immunologic effect (Hibberd 
and Davidson, 2008). Although probiotics have a good 
safety record in humans and are designated as GRAS 
(generally recognised as safe) by the FAO/WHO (Von 
Wright, 2005), when administered to preterm infants and 
neonates, profound analyses and safety aspects should 
be taken into account before considering a probiotic 
therapy. There is a consensus that immune-compromised 
and immune-deficient individuals are more susceptible to 
opportunistic bacteria due to defective microbial clearance. 
At birth, infants do not have a fully developed immune 
system yet and, hence, could be at risk of fungemia and 
bacteraemia after probiotic administration (Boyle et al., 
2006; Maródi, 2006). Indeed, bacteraemia was reported 
in 3 infants with short-bowel syndrome after ingestion 
of L. rhamnosus GG (De Groote et al., 2005; Kunz et al., 
2004). Due to insufficient understanding of the probiotic 
properties and the interaction in the gut, safety predictions 
remain inaccurate. Currently, it is difficult to conclude that 
probiotics are ‘safe’ in infants, as each individual strain has 
to be evaluated for safety at high dosage and chronic use.
In the aftermath of safety issues in pancreatitis, we suggested 
that results with probiotics could never be generalised 
(Maassen and Claassen, 2008) and an extensive (1994-2009) 
exploratory safety analysis of probiotics indicated there is no 
increased health risk (Claassen et al., 2010; Hempel et al., 
2011). However, at that time the authors indicated that, due 
to poorly documented interventions and a lack of adverse 
event (AE) reporting, probiotic safety remains uncertain. 
This report aims to review the safety data of probiotic and 
synbiotic interventions focusing on the infant population 
ageing 0 to 24 months old. Specifically, it will provide an 
update (2008-2013) with the most recent intervention 
studies on the previous safety analysis by Hempel et al. 
(2011). This analysis will provide a clear overview of any 
safety concerns for high-dosage and chronic probiotic use 
in at-risk infant populations, by taking health conditions, 
probiotic intake and study duration into account.
2. Methodology
In order to analyse the safety of probiotics and synbiotics 
in infants, a comprehensive literature study was conducted. 
The online database PubMed (National Library of Medicine, 
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includes MEDLINE) was used as a source for the clinical 
studies. Eligible articles were retrieved using the search 
terms ‘probiotics’, ‘synbiotics’, ‘infants’ and ‘clinical trials’. 
This search strategy was complemented with filters to 
solely include human studies published within the last five 
years (2008-2013). Thereby, all animal and in vitro studies 
were excluded. A full literature search was performed to 
ensure that all the relevant studies were included. All studies 
were subsequently reviewed for clinical phase and status 
using the clinical trials registry databases ‘clinicaltrials.
gov’ and ‘isrctn.org’. The articles were considered eligible 
if the researchers conducted an interventional study using 
a probiotic, a mixture of probiotics or synbiotics in infants 
ageing between 0 and 24 months. All original and follow-
up studies were included, without probiotic species or 
study design restrictions. Both mechanistic studies as well 
as studies attempting to cure, treat, alleviate or prevent 
an illness were incorporated into this analysis. A total 
number of 139 studies describing a probiotic or synbiotic 
intervention in participants ageing from birth to 18 years 
were analysed for applicability based on the abstract of the 
publication. Subsequently, a full text analysis was conducted 
on 128 studies, as 11 studies could not be accessed or were 
not published in English. Forty-nine articles were excluded 
from the safety analysis because not all participants in the 
intervention arms were between 0 and 24 months of age. 
An additional six articles were excluded as no probiotic 
intervention was conducted during the study. Hence, the 
safety analysis was based on 65 studies, of which 57 and 8 
were original and follow-up studies, respectively (Figure 1). 
The remaining eight papers concerned secondary analyses 
on previous studies and were therefore excluded from 
analysis.
The safety profile of the administered probiotics and 
synbiotics were assessed by means of the reported AEs, 
and analysed according to their nature and quantity. AEs 
are defined as the occurrence of complications or illnesses, 
or worsening of the condition throughout the study. AEs 
were categorised according to the Common Terminology 
Criteria for Adverse Events (CTCAE version 4.0, NIH, 2009) 
classification system (Table 1). The CTCAE divides the AEs 
into 26 categories and grades according to the severity. This 
study did not grade the severity of the AEs as these data 
were missing or difficult to interpret. An extra category 
‘unspecified’ was added, as not all reported AEs could be 
properly categorised. AEs were not further subdivided into 
related or serious AEs, because this also depends on the 
judgement of the investigator and unrelated AEs might be 
related in a large meta-analysis. In some studies both the 
mother and infant received probiotic supplements. In these 
cases, only the AEs reported in the infants were taken into 
account. Other relevant data, such as probiotic strains, 
dosage, intervention duration and efficacy, were taken 
Excluded:
no access or not
written in English:
11
Excluded:
intervention on overlapping
subgroup (0-18 years):
49
Excluded:
no probiotic or synbiotic
intervention:
6
Excluded:
substudy/analysis of
previous study:
8
Follow up studies 
analyzed for safety:
8
Original studies 
analyzed for safety:
57
Studies with a probiotic or
synbiotic intervention
(0-24 mo infants):
73
Studies with a probiotic or
synbiotic intervention
(0-18 years):
139
Abstract and title
analysis
Full text
analysis
Safety
analysis
Figure 1. Literature search flow of the safety analysis.
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(1) no disorder, including the subgroups healthy, formula-
fed, caesarean delivered, and at risk of allergy (one or more 
first degree relatives with an allergic disease) infants; (2) 
preterm infants, ranging from healthy to very low birth 
weight (<1,500 g); (3) infants suffering from intestinal 
disorders, which could be subdivided into the subgroups 
diarrhoea, infantile colic, chronic constipation and 
regurgitation; and (4) inflammatory disorders, encompassed 
atopic dermatitis, eczema and cow’s milk allergy.
As illustrated in Figure 2, the majority of infants received L. 
rhamnosus GG. In general, L. rhamnosus GG, Lactobacillus 
reuteri DSM 17938, L. rhamnosus LPR and Bifidobacterium 
longum BL999 were each administered to at least 450 
participants. The strains Bifidobacterium lactis BB-12, B. 
bifidum CUL20, B. bifidum NCDO 1453, B. lactis CUL34, 
Lactobacillus acidophilus NCDO 1748, Lactobacillus 
paracasei CUL08 and Lactobacillus salivarius CUL61 
were supplemented to between 200 and 450 participants 
each. Between 100 and 200 participants received the 
into account for additional analyses. It should be noted 
that this review uses the terms probiotics and synbiotics 
interchangeably, as the synbiotics contain probiotic strains.
3. Results
A total of 10,056 infants, between 0 and 24 months of age, 
were enrolled in the 57 eligible clinical intervention studies 
(analysed studies, Table 2). 5,643 infants were assigned to 
the treatment arm and 4,413 infants to the placebo arm, 
with a drop-out rate of 10.3 and 10.6% respectively. The 
data of the entire allocated population were used in the 
safety analysis, as these include drop-outs due to AEs, 
which are not included in the per-protocol population. Most 
studies were published between 2008 and 2012, whereas 
only one study was published in 2013. The participants 
were recruited according to their respective health status or 
illness, and could be subdivided into the following groups: 
Table 1. The common terminology clinical adverse events 
(CTCAE) version 4.0. The CTCAE is a descriptive terminology, 
which can be utilised for adverse event (AE) reporting according 
to 26 categories. The 27th category ‘unspecified’ was added as 
not all reported AEs could be categorised.
Category Designation
Blood and lymphatic system disorders I
Cardiac disorders II
Congenital, familial and genetic disorders III
Ear and labyrinth disorders IV
Endocrine disorders V
Eye disorders VI
Gastrointestinal disorders VII
General disorders and administration site conditions VIII
Hepatobiliary disorders IX
Immune system disorders X
Infections and infestations XI
Injury, poisoning and procedural complications XII
Investigations XIII
Metabolism and nutrition disorders XIV
Musculoskeletal and connective tissue disorders XV
Neoplasms benign, malignant and unspecified (incl cysts 
and polyps) 
XVI
Nervous system disorders XVII
Pregnancy, puerperium and perinatal conditions XVIII
Psychiatric disorders XIX
Renal and urinary disorders XX
Reproductive system and breast disorders XXI
Respiratory, thoracic and mediastinal disorders XXII
Skin and subcutaneous tissue disorders XXIII
Social circumstances XXIV
Surgical and medical procedures XXV
Vascular disorders XXVI
Unspecified XXVII
Table 2. List of clinical studies evaluated. 
Abrahamsson et al., 2009, 2011
Al-Hosni et al., 2012
Allen et al., 2010
Baldassarre et al., 2010
Basu et al., 2009
Braga et al., 2011
Chouraqui et al., 2008
Chrzanowska-Liszewska et al., 2012
Coccorullo et al., 2010
Dekker et al., 2009
Dutta et al., 2011
Fernández-Carrocera et al., 2012
Firmansyah et al., 2011
Gibson et al., 2009
Gil-Campos et al., 2012
Gore et al., 2012
Grandy et al., 2010
Haschke-Becher et al., 2008
Hascoët et al., 2011
Hol et al., 2008
Holscher et al., 2012
Indrio et al., 2008, 2009, 2011
Kopp et al., 2008
Kuitunen et al., 2009a,b
Kukkonen et al., 2008, 2011
Larsen et al., 2011
Lin et al., 2008
Lodinová-Žádníková et al., 2010
Luoto et al., 2010
Maldonado et al., 2010, 2012
Manzoni et al., 2009, 2011
Mihatsch et al., 2010
Mohan et al., 2008.
Morisset et al., 2011
Nermes et al., 2011
Niers et al., 2009
Ou et al., 2012
Panigrahi et al., 2008
Rautava et al., 2009
Ritchie et al., 2010
Rojas et al., 2012
Romeo et al., 2011
Rose et al., 2010
Rougé et al., 2009
Rozé et al., 2012
Salmi et al., 2010
Samanta et al., 2008
Sari et al., 2012
Savino et al., 2010
Scalabrin et al., 2009
Soh et al., 2009, 2010
Szajewska et al., 2013
Taipale et al., 2011, 2012
Teran et al., 2009
Underwood et al., 2009
Van der Aa et al., 2010, 
2011, 2012
Velaphi et al., 2008
Vlieger et al., 2009
West et al., 2009
Wickens et al., 2012
Yamasaki et al., 2012
Youngster et al., 2011
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probiotic strains Bifidobacterium infantis (unspecified), 
Lactobacillus casei (unspecified), L . acidophilus 
(unspecified), Lactobacillus fermentum CECT5716, B. 
longum (unspecified), B. lactis CNCM I-3446, B. lactis 
HN019, L. rhamnosus HN001, L. rhamnosus (unspecified), 
L. casei CRL-431 (ATCC:55 544), B. bifidum (unspecified), 
L. paracasei ST11 and Bifidobacterium breve (unspecified). 
The other probiotic strains were administered to less than 
100 participants, making their safety data less reliable. 
Probiotic species lacking proper strain designation is due 
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Figure 2. The range of daily cfu intake and participants for each probiotic strain.
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to incomplete intervention description in the original 
studies. Figure 2 demonstrates the evaluated daily dosage 
for each probiotic culture depicted as minimal, maximal 
and average dosage in cfu. On average, the infants received 
a total of 2.79×1010 cfu/day (4.23×109 cfu without the two 
outliers), ranging from a maximal dosage of 2×1012 cfu with 
L. rhamnosus GG to the lowest dosage of 7×106 cfu with 
S. thermophilus (unspecified). The strains L. rhamnosus 
GG, L. rhamnosus LPR (CGMCC 1.3724), B. longum 
BL999 (ATCC:BAA 999), B. lactis Bb-12 (ATCC:27 536), 
B. infantis, L. casei, L. acidophilus, B. longum, L. rhamnosus, 
B. bifidum, Saccharomyces boulardii and L. paracasei 
ST11 were evaluated for multiple dosages, whereas the 
other strains were only assessed at a single dosage or the 
daily applied cfu dosage was missing. As literature did 
not indicate a clear daily cfu dosage, data are missing for 
the strains B. bifidum NCDO 1453, L. acidophilus NCDO 
1748, L. casei CRL-431 (ATCC:55 544), B. breve C50, S. 
thermophilus 065 and L. salivarius CECT5713.
As not all health conditions or disorders require the same 
treatment strategy, particular conditions require specific 
probiotic properties and strains. Nevertheless, most studies 
administered L. rhamnosus, regardless of the infant’s health 
status, except for infants with an immunologic disorder; 
the majority of these infants received B. lactis. In preterms 
and infants with gastrointestinal disorders, L. reuteri was 
the second most frequent studied probiotic, whereas for 
healthy infants and infants with an immune disorder this 
was B. lactis and L. casei, respectively. When analysing on 
a specific strain basis, L. rhamnosus GG is evaluated in the 
majority of studies. However, in healthy infants, this is not 
the most investigated probiotic strain, as the majority of 
participants received B. longum BL999 (n=580). Figure 3 
depicts the number of participants for each probiotic strain 
and the total number of studies performed using this strain, 
analysed for (a) healthy and (b) preterms infants.
Analysis of the study durations is depicted in Figure 4A. 
The mean intervention duration for the 57 trials was 121 
days. Three studies did not define a clear study duration, 
but rather a clinical outcome as endpoint; hence, these 
studies were not being included in this analysis. The 
majority of the participants were exposed to probiotics, 
during a period of 6 months or shorter (46 studies). Only 
one study evaluated the effect of long-term exposure, as 
the participants received probiotics for 2 years. Infants 
suffering from diarrhoea had the shortest exposure (mean 
5 days), whereas the infants at risk of developing an allergy 
received the study product during a mean of 266 days. The 
mean study duration for healthy and formula-fed infants 
was also more than 4 months.
Studies were analysed for the non-specific overall safety 
statement, independently of the reported AEs. These safety 
statements ranged from ‘no AEs were reported during the 
A
B
intervention’ and ‘the study product was well tolerated’ to 
‘increased complications’. As stated in Figure 4B, 28 and 
26% of the studies did not encounter any AEs or the AEs 
were not related to the study product, respectively. There 
was no significant difference in AEs between the treatment 
arm and the placebo arm in 12% of the studies, and 11% of 
the studies stated that the investigational product was well 
tolerated. Notably, 21% of the studies did not discuss or 
report AEs or any safety aspects. One study (2%) reported 
increased complications due to probiotic administration 
(Gore et al., 2012).
The administered dosage per condition is depicted in Figure 
5A. The highest daily dosage range is applied to infants 
suffering from diarrhoeal disease; 2×107 to 2×1012 cfu. 
Infants suffering from other gastrointestinal disorders, 
such as regurgitation and constipation, received on average 
the lowest cfu per day. Surprisingly, all formula-fed infants 
received a total of 1×1010 cfu per day. The lowest daily 
dosage of 7×106 was administered to preterm (low-birth-
weight) infants, however they were exposed to an average 
of 2×109 cfu per day.
Data from the follow-up studies did not indicate any 
safety concerns. A 10-year follow-up study by Luoto et al. 
(2010) reported no AEs or any effect on growth pattern 
and development of obesity by L. rhamnosus GG. Van 
der Aa et al. (2011) demonstrated that, after a follow-up 
period of one year, infants receiving B. breve M-16V had 
less asthma-like symptoms compared to the placebo group. 
In addition, Kukkonen et al. (2008) showed that a mix of 
probiotics is safe on the long-term and increased resistance 
to respiratory infections.
The number of participants allocated and analysed ‘per 
protocol’ for each infant health condition is shown in Figure 
6A. The majority of infants subjected to an intervention 
were preterms, infants at risk of allergy and healthy 
infants, respectively. The most common reported AEs 
were ‘diarrhoea’, ‘respiratory infections’, ‘gastrointestinal 
infections’, ‘sepsis’ and ‘fever’. Please note that this in 
itself is not surprising, since these effects were also the 
main clinical outcomes to be influenced by probiotics. 
However, in view of AE reporting this should not induce 
a bias in properly conducted studies. A total of 5,147 
AEs were reported in the treatment and placebo group 
together. AEs in the category of infections and infestations 
(category XI) occurred most frequently, followed by 
gastrointestinal symptoms (category VII), respiratory, 
thoracic and mediastinal disorders (category XXII), and 
general disorders and administration site conditions, such 
as fever (category VIII). Figure 6B shows the distribution 
of AEs for the various CTCAE categories for all probiotic 
intervention arms and non-probiotic control arms. The AEs 
that occurred in the other categories were relatively rare. 
When focussing more closely on reported AEs within the 
ht
tp
://
w
w
w
.w
ag
en
in
ge
na
ca
de
m
ic
.c
om
/d
oi
/p
df
/1
0.
39
20
/B
M
20
13
.0
04
6 
- W
ed
ne
sd
ay
, M
ay
 1
8,
 2
01
6 
12
:2
5:
34
 A
M
 - 
IP
 A
dd
re
ss
:1
30
.1
15
.1
33
.2
51
 
 Probiotic and synbiotic safety in infants under two years of age
Beneficial Microbes 5(1) 51
C
ul
tu
re
s
L. rhamnosus GG
B. infantis
L. casei
L. acidophilus
B. longum
B. bifidum OLB6378
B. bifidum
S. thermophillus
L. rhamnosus
L. reuteri DSM 17938
L. reuteri (ATCC:55730)
L. reuteri
L. plantarum
L. acidophilus NCDO 1748
B. longum BB536
B. lactis BB12
B. infantis  35624
B. bifidum NCDO 1453
B. breve
Participants (n)
1.20010008006004002000
Studies (n)
6420
Participants per culture in preterm infantsA
C
ul
tu
re
s
L. rhamnosus GG
B. longum BL999 (ATCC:BAA 999)
L. rhamnosus LPR (CGMCC 1.3724)
B. lactis Bb-12 (ATCC:27 536)
L. fermentum CECT5716
B. lactis CNCM I-3446
S. thermophilus 065
L. salivarius CUL61
L. salivarius CECT5713
L. rhamnosus HN001
L. rhamnosus (LCS-742)
L. reuteri
L. paracasei ST11 (CNCM I-2116)
L. paracasei F19
L. paracasei CUL08
L. lactis W58
L. johnsonii La1
L. casei CRL-431 (ATCC:55 544)
L. plantarum (ATCC:20195)
E. coli  O83:K24:H31
B. lactis W52
B. lactis HN019
B. breve C50
B. bifidum W23
B. bifidum CUL20
B. animalis subsp. lactis CUL34
B.  longum subsp infantis M63
Participants (n)
6005004003002001000
Studies (n)
6543210
Participants per culture in healthy infants (0-2 yr)B
Figure 3. Participants and number of studies per culture in (A) preterm and (B) healthy infants. The gray bar represents the number 
of participants, the asterisk is the number of studies.
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specific infant conditions, infections and infestations (XI) 
are most prevalent in preterm infants. In category XI, 100 
more AEs were reported in the treatment arm compared 
to the control group. The incidence of gastrointestinal 
symptoms was lower in the verum group (Figure 6C). In 
infants suffering from diarrhoea, more AEs are reported 
in the treatment group for all CTCAE categories, although 
the number of AEs is very low compared to the number 
of allocated participants (Figure 6D). When focussing on 
reported AEs in infants with dermatitis, eye disorders 
(VI), gastrointestinal symptoms (VII) and immune 
system disorders (X), AEs are more frequently observed 
in treatment group compared to the placebo group, whereas 
skin and subcutaneous tissue disorders (XXIII) were less 
frequently reported in the treatment group (Figure 6E). In 
formula-fed infants, all AEs occurred more frequently in 
the control group, with the highest prevalence of infections 
and infestations (XI) (Figure 6F). In the healthy infant 
population, infections and infestations were most commonly 
observed, whereas in infants at-risk of developing an allergy, 
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Figure 4. Histogram of (A) duration of each study in days and (B) the percentage of studies reporting a general safety statement. 
AEs = adverse events.
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Figure 5. Range of evaluated interventional dose per day for each infant health status; minimal, average and maximal cfu per day. 
Condition ‘other’ entails cow’s milk allergy and vaccinated infants.
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Figure 6. (A) Participants allocated and analysed per protocol of the verum and placebo group for each health condition. (B) The 
total adverse events (AEs) reported of all studies, comparing placebo and verum group and categorised according to the Common 
Terminology Clinical Adverse Events (CTCAE). (C) Reported AEs categorised according to CTCAE analysed for preterm infants, 
(D) infants with diarrhoea, (E) infants with dermatitis, and (F) formula-fed infants.
ht
tp
://
w
w
w
.w
ag
en
in
ge
na
ca
de
m
ic
.c
om
/d
oi
/p
df
/1
0.
39
20
/B
M
20
13
.0
04
6 
- W
ed
ne
sd
ay
, M
ay
 1
8,
 2
01
6 
12
:2
5:
34
 A
M
 - 
IP
 A
dd
re
ss
:1
30
.1
15
.1
33
.2
51
 
M. van den Nieuwboer et al.
54 Beneficial Microbes 5(1)
gastrointestinal symptoms (VII) occurred more frequently. 
In addition, the incidence of AEs that could be categorized 
as gastrointestinal symptoms (VII, 207 and 180), fever 
episodes (VIII, 189 and 186) and respiratory, thoracic and 
mediastinal disorders (XXII) were high (n=226 and 197 
for the treatment and placebo, respectively) in healthy 
infants. In infants affected by gastrointestinal disorders 
other than diarrhoea, few AEs were reported and often of 
gastrointestinal of nature (data not shown).
4. Discussion and conclusions
Analysis of the 57 clinical trials with probiotics and 
synbiotics in combination with eight follow-up studies, 
published between 2008 and 2013, indicate that probiotic 
administration to infants between 0 and 24 months is 
safe with regard to the evaluated strains in infants with 
a particular health status or susceptibility. Most AEs and 
serious AEs were considered unrelated to the study product, 
and there were no major safety concerns. Almost all studies 
concluded that none of the AEs were related to the study 
product and the study products are generally well tolerated. 
Only a single study reported increased complications, such 
as green loose stools, increased vomiting, feed-refusal or 
colic, although, prevalence and significance of AEs was not 
described (Gore et al., 2012). This study analysed whether 
dietary supplementation of infants with eczema at age 3-6 
months with probiotics had a treatment effect or altered 
allergic disease progression. These infants ingested L. 
paracasei CNCM I-2116 or B. lactis CNCM I-3446 in 
combination with an extensively hydrolysed (EH) infant 
formula. This EH-infant formula could well have induced 
the AEs, as other studies using L. paracasei CNCM I-2116 
and B. lactis CNCM I-3446 do not report any significant 
AEs (Chouraqui et al., 2008; Gibson et al., 2009; Velaphi 
et al., 2008). Gore and colleagues did also not report any 
significant clinical effect between the study groups, whereas 
previous studies analysing the effect of other probiotics in 
infants with eczema demonstrate a positive clinical results 
and no AEs (Weston et al., 2005; Rosenfeldt et al., 2003).
The data of this review indicate that there is no significant 
difference in the number of AEs between the probiotic 
and the control group; both in the total population as well 
as in the specific health conditions. A total of 2,589 and 
2,558 AEs were reported in the treatment and control 
group, respectively. This subtle difference of 31 more 
AEs in the treatment arm is not significant as 1,230 more 
participants were allocated to this arm and hence relatively 
more AEs occurred in the control group (incidence rate 
of an AE=0.458 in the treatment group vs. 0.579 in the 
placebo group, respectively). The largest difference in 
participant allocation between treatment and placebo 
group was observed in the preterm study population. This 
deviation could be attributed to the retrospective study of 
Manzoni et al. (2011), analysing the effect of L. rhamnosus 
GG supplementation in preterm infants. This study did 
not include a control group, which explains the higher 
observed frequency of AEs. In particular, Manzoni et al. 
(2011) documented 142 cases of late-onset sepsis, in the 
category infections and infestations (XI). This explains that 
more AEs are observed in the probiotic group in category 
(XI). If these cases were subtracted from the total reported 
AEs in category XI, 86 more infections and infestations 
occurred in the control group. This would be consistent 
with other reports in the literature indicating that probiotics 
reduce the incidence of infections (Maldonado et al., 2012; 
Manzoni et al., 2009; Taipale et al., 2011).
Despite that 984 infants with diarrhoea were allocated 
to the treatment or control arm, surprisingly very few 
(18) AEs were reported in these studies. A proportion of 
these infants received a very high daily dosage of 2×1012 
cfu L. rhamnosus GG, with no significant difference in 
AEs (Basu et al., 2009). These data are encouraging and 
further underpin the evidence that L. rhamnosus GG is 
safe in infants, even at a very high dosage. The strain L. 
rhamnosus GG is well characterised and evaluated in a large 
population sample at varying dosages. Unfortunately, this 
is not the case for many other potential beneficial probiotic 
strains. For many infant health conditions, daily intake did 
not exceed 1×1010 cfu. Especially in healthy infants, the 
range of administrated dosage is relatively narrow, and 
these infants are the least susceptible for complications 
compared to other health conditions. Examining higher 
probiotic exposure in this healthy group could facilitate the 
establishment of the optimal dosage for infants.
In infants affected by dermatitis, the number of AEs in 
the category eye disorders (VI) and allergies (X) were 
substantially higher in the treatment group compared to 
placebo. This was mainly due to the study by Gore et al. 
(2012) that observed significantly more frequently itchy 
and red eyes at the age of 12 months in the probiotic group. 
However this significant difference was not persistent at 
later visits. Whether this is due to the EH-infant formula 
or the probiotic strains should still be determined.
Despite the large number of reported AEs in the clinical 
trials, only 21 studies observed a significant difference in 
AEs between the treatment and control arm. In most of 
these cases, probiotic treatment had a protective effect; in 
the control groups the frequencies of the occurred AEs were 
significantly higher. Despite these encouraging results, there 
were some safety concerns. Scalabrin et al. (2009) reported 
excessive crying in formula-fed infants and Kopp et al. 
(2008) observed a significant higher incidence of recurrent 
wheezing bronchitis in infants at risk of allergy after L. 
rhamnosus GG supplementation. Although a significant 
safety concern, this only occurred in a small sample (n=54) 
and was not observed in any other analysed clinical study 
with L. rhamnosus GG. In contrast to the other clinical 
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trials, probiotic administration of B. longum BL999 and 
L. rhamnosus LPR induced more episodes of diarrhoea 
in healthy infants compared to placebo (Firmansyah et 
al., 2011). This increase in diarrhoea might be due to the 
fructose-oligosaccharide or other prebiotic additives in 
the study product, which were not present in the control 
product. The majority of analysed studies do not indicate 
any difference in respiratory tract infections between either 
intervention arms, or even demonstrate a slight protective 
effect against respiratory tract infections. Nevertheless, 
Allen et al. (2010) observed a higher frequency of lower 
respiratory tract infections when exposed to a probiotic 
mixture of L. salivarius CUL61, L. paracasei CUL08, 
Bifidobacterium animalis subsp. lactis CUL34 and B. 
bifidum CUL20.
No study reported a bacteraemia or fungemia associated 
with the ingested probiotics. This is in line with the 
literature. Since 1980s, there has been no increase in 
frequency of Lactobacillus associated bacteraemia cases 
in Finland, despite a substantial increase in probiotic 
use (Salminen et al., 2002). Clinical infections, such as 
bacteraemia and myocarditis, are rarely (over a period 
of 10 years covering an population of 1.3 million persons 
where probiotics are standard in the diet; Salminen et al., 
2002) associated with the use of the probiotics Lactobacillus 
or Bifidobacterium. Also in a large study (in subjects 
with severe underlying disease!) evaluating 89 cases of 
Lactobacillus bacteraemia (unrelated to probiotic intake) 
treatment with antimicrobials was effective both in vitro 
and in reducing mortality (odds ratio = 0.22; Salminen et 
al., 2004). In another very large survey, only 12 cases of 
bacteraemia were reported concurrent with the use of L. 
rhamnosus GG, 5 cases with Bacillus subtilis and 1 case 
with L. acidophilus. There were only 27 reports of fungemia 
when the yeast S. boulardii concurrently was administered, 
and the authors concluded probiotics are safe but results 
cannot be generalised for other or new/future strains (Boyle 
et al., 2006).
Although the primary goal was not to identify the efficacy 
of probiotic interventional studies, most studies reported 
a significant beneficial clinical outcome effect. Increased 
stool frequency, softer stools and reduced diarrhoea 
were among the most common clinical effects. Despite 
the limited overall effects, in specific health conditions, 
such as preterms and infants suffering from diarrhoea, 
results are more promising; probiotics seem to prevent 
NEC (Bell’s stage II and higher) and reduce the duration 
and hospitalisation in diarrhoea (Fernández-carrocera 
et al., 2012; Grandy et al., 2010; Lin et al., 2008; Teran 
et al., 2009). Nevertheless, 11 studies did not report any 
significant effect in the treatment arm compared to the 
control group, thereby maintaining the controversy of 
probiotic efficacy. Large meta-analyses should provide 
overall benefit/risk analyses and conclusions, and underpin 
policies for implementation of probiotic treatment.
Based on the study by Hempel et al. (2011) combined with 
the current data, we still cannot provide a decisive safety 
profile of probiotics and synbiotics. The documentation of 
the clinical studies is poor, as they lack details regarding AEs, 
the specific identity of probiotic strains and administered 
dosage. Very few studies address specifically probiotic 
complications and are not designed to assess the safety 
profile. Additionally, safety should be evaluated on a strain-
by-strain basis, depending on long-term and high dosage 
exposure.
A major pitfall of this safety analysis is the lack of consistent 
AE reporting. Many studies do not provide the incidence 
of AE, however, only state that ‘no significant difference 
in complications was observed between the study groups’. 
Studies fail in particular to report the frequency of more 
common AEs, such as diarrhoea, vomiting, regurgitation, 
fever and flatulence, and focus more on irregular AEs. 
Incidences of serious AEs are often not well described and 
designated as unrelated to the study product, while large 
meta-analyses could give new insight in the causal relation 
of AE and the use of probiotics. The lack of this data inhibits 
a clear overview of the incidence of real complications and 
explains potential underrepresentation of certain CTCAE 
categories.
Another major flaw is the incorrect documentation 
of probiotic strains. Probiotics should be properly 
characterised according to the taxonomy, including 
specific strain and culture. Many studies fail to do this. 
Since beneficial effects on the host can only be attributed 
to a specific culture, selecting the correct probiotic strain is 
essential. Even if bacteria share the same genus and species, 
their properties can differ significantly and thus need to 
be tested individually (Van Baarlen et al., 2011). Another 
shortcoming is that not all studies provide and mention 
a clear daily dosage (cfu) and duration of intervention. 
Studies that administer infant formula supplemented 
with probiotics do indicate the cfu/g; however, they fail 
to indicate the ingested cfu/day. A minimal concentration 
of probiotics is necessary to gain successful colonisation, 
which is often transient of nature (Petschow et al., 2005). 
This missing data prevents the establishment of an optimal 
dose-response relationship. A higher probiotic dosage 
could induce a higher incidence of AEs. This review shows 
that the ranges of evaluated dosages are narrow for many 
infant conditions, and few studies administered probiotics 
at very high dosages. Research should focus on the efficacy 
of a single probiotic, a probiotic mixture or synbiotics. To 
obtain reliable data, studies should be well designed to test 
efficacy, preferably randomised, placebo controlled, double 
blinded studies. It is of importance that the probiotics 
or synbiotics have a well-defined target population. By 
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evaluating safety and efficacy on subgroups, including 
high-risk groups, the beneficial health effects can only be 
attributed to specific probiotic strains and for a certain 
health status. Investigators and industry should be aware 
that strain specific safety and efficacy data on particular 
patient populations should not be extrapolated to other 
probiotic strains or target populations.
5. Recommendations
Based on the probiotic format, target indication and mode 
of administration, a probiotic product can be characterised 
as a food, food supplement, biological or pharmaceutical 
product. These products are all subject to different 
regulations, which complicates safety guidelines and health 
claims. If probiotic products are used to prevent, treat, 
or alleviate a medical condition, the product should be 
considered as a biological product and evaluated according 
to the International Conference on Harmonisation of 
Technical Requirements – Good Clinical Practice and 
medical product procedures to produce consistent safety 
and efficacy data. This includes detailed descriptions of the 
studied product, and a comprehensive AE documentation.
Each new probiotic strain should be analysed for properties, 
including genomics, to understand the mode of action. 
Metabolic mechanisms, interaction with the host immunity 
and ability to exchange virulence factors with pathogens 
is essential for a comprehensive safety profile. Even if the 
probiotic strain is considered safe, it can still become 
opportunistic and cause bacteraemia. Probiotics should 
be considered safe if they at least fulfil the following specific 
criteria: (a) the probiotic strain should be properly isolated 
and classified according to the correct taxonomy; (b) 
manufactured according to good manufacturing practices 
to eliminate contamination with other microbes, probiotics 
or substances; (c) a clear overview of the safety (according 
to standardised and accepted CTCAE) and toxicity levels 
associated with the probiotic administration; and (d) a 
clear evaluation of the target population, including high 
risks groups such as infants and immune deficient patients.
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